[Lenalidomide; adverse effects and commercialisation]
Farm Hosp
.
2008 Nov-Dec;32(6):358-60.
doi: 10.1016/s1130-6343(08)76285-8.
[Article in Spanish]
Authors
L Ortega Valín
,
J J del Pozo Ruiz
,
C Rodríguez Lage
,
F Ramos Ortega
PMID:
19232222
DOI:
10.1016/s1130-6343(08)76285-8
No abstract available
Publication types
Letter
MeSH terms
Antineoplastic Agents / adverse effects*
Commerce
Female
Humans
Lenalidomide
Male
Thalidomide / adverse effects
Thalidomide / analogs & derivatives*
Substances
Antineoplastic Agents
Thalidomide
Lenalidomide